rs7540214 — IFNLR1 IFNLR1 variant

Intronic variant in the interferon lambda receptor 1 gene that elevates PsA risk by amplifying IL-29/IFN-lambda signaling in synovial tissue, marking those with skin psoriasis who are at elevated risk for progressing to joint disease

See your personal result for IFNLR1

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

IFNLR1 rs7540214 — The Psoriasis-to-Arthritis Transition Signal

Most people with psoriasis never develop joint disease. But roughly 30% do — and predicting who is at risk before joint damage begins is one of the central challenges in psoriatic disease management. The rs7540214 variant sits in the IFNLR1 gene, which encodes the interferon lambda receptor 111 interferon lambda receptor 1
Also known as IL-28Rα; partners with IL-10RB to form the type III interferon receptor complex that binds IL-28A, IL-28B, and IL-29, and it emerged from a large-scale genome-wide analysis as a genetic signal that specifically marks psoriatic arthritis risk rather than skin-only psoriasis.

The Mechanism

Type III interferons (IFN-lambdas) were long thought to act mainly at epithelial barriers — protecting the skin, gut lining, and airways against viral entry. The IFNLR1 receptor complex is expressed on epithelial cells, keratinocytes, and innate immune cells at these surfaces. But accumulating evidence shows that the type III interferon axis extends into synovial joints22 type III interferon axis extends into synovial joints
IL-28Rα is expressed on synovial fibroblasts and macrophages; joint fibroblasts release IL-29 in response to innate immune stimuli: fibroblasts lining the joint cavity express IFNLR1, respond to IL-29, and in turn amplify the joint inflammatory cascade.

The biological consequences of excess IL-29/IFNLR1 signaling in joint tissue are well-characterized. IL-29 stimulates synovial fibroblasts to produce IL-6, IL-8, and MMP-333 stimulates synovial fibroblasts to produce IL-6, IL-8, and MMP-3
Matrix metalloproteinase-3 degrades extracellular matrix components, contributing to cartilage destruction and to upregulate RANKL expression via ERK, p38, and JNK MAPK pathways44 upregulate RANKL expression via ERK, p38, and JNK MAPK pathways
RANKL (receptor activator of NF-κB ligand) drives osteoclast differentiation and is the direct molecular mediator of bone erosion in inflammatory arthritis. It also enhances TLR4-mediated production of TNF-α55 enhances TLR4-mediated production of TNF-α
Via NF-κB pathway activation, creating a feed-forward loop between innate immune sensing and interferon signaling. Within the joint cavity, intra-articular granzyme M triggers IL-29 release from fibroblasts66 intra-articular granzyme M triggers IL-29 release from fibroblasts
GrM levels are elevated in RA synovial fluid and correlate with IL-29; purified GrM stimulates IL-29 secretion in vitro, providing an amplification loop specific to inflamed joints.

The rs7540214 T allele tags a haplotype that may alter IFNLR1 expression or receptor complex activity in joint-resident cells. A 2025 Mendelian randomization study found that elevated IFNLR1 protein levels are causally associated with PsA risk77 elevated IFNLR1 protein levels are causally associated with PsA risk
IFNLR1 expression is significantly upregulated by 48-hour co-stimulation with IL-17A and IL-23 — the cytokines that dominate psoriatic disease pathogenesis, and that IFNLR1 is among the few proteins showing a positive causal association in proteome-wide MR.

The Evidence

The primary genetic evidence comes from a 2015 GWAS meta-analysis by Stuart et al.88 2015 GWAS meta-analysis by Stuart et al.
3,061 PsA cases, 3,110 cutaneous-only psoriasis cases, and 13,670 controls of European descent across six discovery studies that systematically compared the genetic architectures of psoriatic arthritis and skin-limited psoriasis. Among ten loci achieving genome-wide significance for PsA, IFNLR1 was specifically flagged as a novel association that had not previously reached genome-wide significance — and critically, as a locus differentiated between PsA and cutaneous-only disease. This PsA-specificity is the key clinical interpretation: the variant does not simply tag psoriasis susceptibility in general, but marks the subset of psoriasis patients at elevated risk for joint involvement.

Beyond direct genetic association, the IFNLR1-PsA link has biological support from multiple mechanistic streams. IFNLR1 variants (including rs4649203 in the same gene) have been associated with rheumatoid arthritis and systemic lupus erythematosus99 rheumatoid arthritis and systemic lupus erythematosus
rs4649203-G associated with SLE and RA occurrence, with disease sub-phenotype effects on serositis, anemia, vasculitis, and nodule formation, establishing that IFNLR1 genetic variation shapes broad inflammatory arthritis risk, not just psoriatic disease.

Practical Implications

Carrying the T allele — either as CT heterozygous or TT homozygous — does not cause arthritis. The large majority of T allele carriers with psoriasis will not develop joint disease. However, this variant provides meaningful prior probability information that can sharpen monitoring decisions. For someone already diagnosed with psoriasis, an rs7540214 T allele should prompt attention to joint symptoms that might otherwise be attributed to mechanical causes: morning stiffness lasting more than 30 minutes, pain in distal interphalangeal joints (especially with nail changes), lower back pain with inflammatory features (worse at rest, improved with movement), or dactylitis (sausage finger/toe).

Biologics targeting the IL-23/IL-17 axis — the same cytokines that upregulate IFNLR1 expression — form the cornerstone of PsA treatment. This genetic background may be one reason why IL-23 blockade is particularly effective in PsA: suppressing IL-23 reduces the co-stimulatory signal that drives IFNLR1 upregulation in joint fibroblasts.

Interactions

IFNLR1 signaling intersects with the broader type I interferon system (IFN-alpha/beta) that is amplified by IRF5 variants (rs10488631). Both type I and type III interferons drive overlapping proinflammatory gene programs in synovial tissue. An individual carrying risk alleles at both IRF5 and IFNLR1 would have amplification at two distinct nodes of the interferon axis — a combination that has not been formally studied in PsA but warrants investigation given the additive effects documented for IRF5 variants in other autoimmune conditions.

The IFNLR1 locus has also been fine-mapped at the chromatin level: a nearby variant (rs10794648) at this locus was linked to GRHL3 through chromatin looping in dermatological risk loci studies, suggesting that the functional impact may extend beyond IFNLR1 itself to regulatory elements controlling epithelial barrier gene expression.

Genotype Interpretations

What each possible genotype means for this variant.

CC Standard Joint Risk Normal

Common IFNLR1 genotype; no elevated genetic risk for psoriatic arthritis via this variant

You carry two copies of the common C allele at rs7540214 in the IFNLR1 gene. This is by far the most frequent genotype globally — approximately 76% of people worldwide share this genotype, with rates of 74% in Europeans and slightly higher in African and Latino populations (~80%). Your type III interferon receptor activity at this locus is at population-typical levels, and this variant does not elevate your genetic risk for psoriatic arthritis. If you have or develop psoriasis, this particular locus does not point toward elevated joint involvement risk.

CT Elevated PsA Risk Intermediate

One copy of the IFNLR1 risk allele; moderately elevated risk for psoriatic arthritis

The IFNLR1 T allele at rs7540214 emerged from a 2015 GWAS meta-analysis of 3,061 psoriatic arthritis cases as one of ten novel genome-wide significant loci for PsA. Its significance was specifically for PsA rather than skin-only psoriasis, establishing it as a variant that modulates the skin-to-joint transition rather than psoriatic disease susceptibility in general.

Mechanistically, IFNLR1 encodes the alpha chain of the type III interferon receptor, which forms a complex with IL-10RB to bind IL-28A, IL-28B, and IL-29. In the joint compartment, synovial fibroblasts and macrophages express this receptor and respond to IL-29 by upregulating RANKL (a direct osteoclast activator), MMP-3 (a cartilage- degrading enzyme), IL-6, IL-8, and TNF-alpha. A 2025 Mendelian randomization study confirmed that elevated IFNLR1 protein levels are causally associated with PsA risk and that IFNLR1 expression is upregulated by IL-17A and IL-23 — the dominant cytokines in psoriatic disease.

As a heterozygote, you have intermediate receptor sensitivity. One T allele is likely sufficient to modestly increase IFNLR1-mediated signaling in joint-resident cells when inflammatory triggers are present, without reaching the amplified signaling seen in TT homozygotes.

TT High PsA Risk High Risk

Two copies of the IFNLR1 risk allele; substantially elevated genetic risk for psoriatic arthritis

TT homozygotes carry the maximal IFNLR1 risk burden at this locus. Both receptor complexes in every joint-resident cell run on the T-allele haplotype, which — based on the mechanistic literature and MR data — confers the highest signaling sensitivity to IL-29 stimulation. In the joint microenvironment, this translates to greater RANKL upregulation (amplified bone erosion signaling), higher MMP-3 output (cartilage degradation), and stronger TNF-alpha and IL-6 production in response to innate immune triggers. The 2025 MR study found that IFNLR1 protein levels are positively and causally associated with PsA — meaning higher expression is not protective but pathogenic in this context. TT homozygotes are likely at the upper end of that causal distribution.

The GWAS that established rs7540214 as a PsA locus explicitly distinguished PsA from cutaneous-only psoriasis, placing IFNLR1 among a small set of variants that predict joint transition rather than skin disease severity. For TT homozygotes with psoriasis, the annual risk of developing PsA (epidemiologically estimated at roughly 2–3% per year in general psoriasis cohorts) is likely meaningfully higher, though population-stratified figures for TT specifically are not yet published.

IFNLR1 genetic variation has also been linked to RA and SLE susceptibility, confirming that this receptor modulates inflammatory arthritis risk across disease categories.